Psoriasis: Inhibition of the IL-17 signaling pathway with secukinumab;Psoriasis: Hemmung des IL-17-signalwegs durch secukinumab

Medizinische Monatsschrift fur Pharmazeuten

Volumn 37, Issue 7, 2014, Pages 267-268

  Recker, Katrina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; SECUKINUMAB;

NOTE; PSORIASIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INTERLEUKIN-17; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 84904248348     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Nast A, et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris. JDDG 2011;9(Suppl 2):S1-95.
2. Dubertret L, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36.
3. Yeung H, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013;68:64-72.